NBIO (Nascent Biotech) Inventory Turnover: 0.00 (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nascent Biotech Inventory Turnover?

Nascent Biotech NBIO Inventory Turnover is 0.00 as of Jun. 2024.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Nascent Biotech's Cost of Goods Sold for the three months ended in Jun. 2024 was $0.00 Mil. Nascent Biotech's Average Total Inventories for the quarter that ended in Jun. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Nascent Biotech  (OTCPK:NBIO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Nascent Biotech's Days Inventory for the three months ended in Jun. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Nascent Biotech's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Nascent Biotech Inventory Turnover Related Terms

Nascent Biotech Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Inventory Turnover Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventory Turnover
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nascent Biotech Inventory Turnover Calculation

Nascent Biotech's Inventory Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Inventory Turnover (A: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Mar. 2024 ) / ((Total Inventories (A: Mar. 2023 ) + Total Inventories (A: Mar. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Nascent Biotech's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover (Q: Jun. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2024 ) / ((Total Inventories (Q: Mar. 2024 ) + Total Inventories (Q: Jun. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Nascent Biotech (NBIO) has a Inventory Turnover of 0.00 as of Jun. 2024. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Inventory Turnover too high?
Nascent Biotech's current Inventory Turnover is 0.00.
How does Nascent Biotech's Inventory Turnover compare to BTAX and PXMD?
Nascent Biotech's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Inventory Turnover is 0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.